Abstract
A series of aryltetrazolylacetanilides was synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors on wild-type virus and on the clinically relevant K103N mutant strain. Extensive SAR investigation led to potent compounds, with nanomolar activity on K103N, and orally bioavailable in rats.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetanilides / chemistry
-
Acetanilides / pharmacology*
-
Animals
-
HIV Reverse Transcriptase / antagonists & inhibitors*
-
HIV-1 / drug effects*
-
HIV-1 / enzymology
-
HIV-1 / genetics
-
Mutation*
-
Rats
-
Reverse Transcriptase Inhibitors / chemistry
-
Reverse Transcriptase Inhibitors / pharmacology*
-
Structure-Activity Relationship
Substances
-
Acetanilides
-
Reverse Transcriptase Inhibitors
-
HIV Reverse Transcriptase
-
thioacetanilide